Palatin Technologies Inc - Company Profile
Powered by 
All the data and insights you need on Palatin Technologies Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Palatin Technologies Inc Strategy Report
- Understand Palatin Technologies Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Palatin Technologies Inc (Palatin) is a biopharmaceutical company that develops receptor specific peptide therapeutics. The company’s medicines are based on molecules that control the activity of the melanocortin and natriuretic peptide receptor systems. Its lead product Vyleesi, is indicated for the treatment of premenopausal women with hypoactive sexual desire disorder. Palatin clinical pipeline includes melanocortin receptor programs such as PL-8177 MC1r Agonist (oral) for inflammatory bowel disease; PL9643 MCr Agonist for dry eye diseases; PL-8177 MC1r Agonist (systemic) for ulcerative colitis; and MC4r Agonist for diabetic retinopathy. Palatin is headquartered in Cranbury, New Jersey, the US.
Headquarters
United States of America
Address
4b Cedar Brook Drive, Cranbury, New Jersey, 08512
Website
www.palatin.com
Telephone
1 609 4952200
No of Employees
34
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PTN (AFM)
Revenue (2022)
$4.9M
230.5%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
23.9%
(2022 vs 2021)
Market Cap*
$29.7M
Net Profit Margin (2022)
XYZ
77.0%
(2022 vs 2021)
* As of and is in US$
Palatin Technologies Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Product Pipelines: | Vyleesi |
| Melanocortin Receptor Programs | Palatin |
| Bremelanotide MC4r Agonist(Vyleesi): | Palatin Technologies |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In August, the company entered into a partnership with UpScriptHealth. |
| 2019 | Regulatory Approval | In June, the company received approval for Vylees (bremelanotide injection) from the USFDA for the treatment of acquired generalized hypoactive sexual desire disorder. |
| 2019 | Regulatory Approval | In June, the company received orphan drug designation for PL-8177 from the USFDA for the treatment of non-infectious uveitis. |
Competitor Comparison
| Key Parameters | Palatin Technologies Inc | Johnson & Johnson | Neurocrine Biosciences Inc | Ardelyx Inc | Rigel Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Cranbury | New Brunswick | San Diego | Fremont | South San Francisco |
| State/Province | New Jersey | New Jersey | California | California | California |
| No. of Employees | 34 | 131,900 | 1,400 | 267 | 147 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Carl Spana, Ph.D. | Director; Chief Executive Officer; President | Executive Board | 2000 | 60 |
| Stephen T. Wills | Executive Vice President; Chief Financial Officer; Chief Operating Officer; Treasurer; Secretary | Senior Management | 2011 | 66 |
| Stephen A. Slusher | Assistant Secretary; Chief Legal Officer | Senior Management | 2006 | - |
| Michael B. Raizman, M.D. | Chief Medical Officer | Senior Management | 2021 | - |
| John K.A. Prendergast, Ph.D. | Chairman | Non Executive Board | 2000 | 69 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward